EyePoint, Inc. - 8-K Filing
EyePoint's DURAVYU failed primary endpoint in LUCIA Phase 3 trial for wet AMD despite meeting key secondary endpoints and showing reduced treatment burden (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
EyePoint's DURAVYU failed primary endpoint in LUCIA Phase 3 trial for wet AMD despite meeting key secondary endpoints and showing reduced treatment burden (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)